The Healthline report on the JAHA study correctly flags perimenopause as a 'window of opportunity,' yet underplays its observational design and modest effect sizes while overlooking how these findings fit a decade-long pattern of under-detection in women. The analysis, drawn from NHANES data and scored via AHA Life’s Essential 8, showed perimenopausal participants (mean age 50.5) scoring 4.2 points lower than premenopausal peers after age adjustment; however, no randomized trial evidence yet tests whether targeted interventions during this window alter hard outcomes such as MI or stroke. Two additional peer-reviewed sources sharpen the picture. The Study of Women’s Health Across the Nation (SWAN), an ongoing observational cohort of 3,302 women, documented accelerated carotid intima-media thickening and a 1.5-fold rise in insulin resistance precisely during the menopausal transition (El Khoudary et al., Circulation 2020), independent of chronological age. A 2022 meta-analysis of 15 cohorts (n=312,000) confirmed a 24% higher relative risk of CVD events in women experiencing early menopause, with strongest signals in those with adverse lipid shifts (Zhu et al., Lancet Diabetes Endocrinol). Both studies share the same limitation as the JAHA paper: reliance on observational data prone to residual confounding and self-reported menopausal status. What prior coverage missed is the absence of conflict-of-interest disclosures around statin or hormone-therapy sponsors and the failure to stratify by race/ethnicity, despite SWAN showing steeper declines among Black participants. The larger pattern is systemic: women aged 45–55 remain 30–40% less likely than men to receive guideline-directed lipid or glucose screening (Goff et al., Circulation 2023), even as visceral adiposity and endothelial dysfunction accelerate. Perimenopause therefore represents not merely an individual lifestyle moment but a population-level inflection where sex-specific risk algorithms and proactive metabolic monitoring could close the persistent sex gap in cardiovascular mortality.